samedan logo
 
 
 
spacer
home > ebr > summer 2021 > crispr: the jump from bench to clinic
PUBLICATIONS
European Biopharmaceutical Review

CRISPR: The Jump From Bench to Clinic

CRISPR and other genome editing tools have shown great promise as new therapeutics in vitro. The technology has advanced rapidly, and the potential for life-changing therapies has been demonstrated over and over. The real problem facing CRISPR, and all genome editing tools now, is one of scalability and reproducibility. What has been shown in the laboratory now needs to be robustly demonstrated on much larger scales and the results must be the same every single time.

Not only that, the leap from in vitro lab bench to in vivo clinical studies is huge. Performing a CRISPR experiment in a cell culture dish lacks most of the complexity of human cells embedded in a complex tissue system. We have to be prepared to encounter and overcome these problems if genome editing is to become a real therapeutic option in the future. We have been down this road to a certain extent with small molecule drugs for cancer and biologics. We know that factors such as tumour microenvironments, immune responses, and tissue hypoxia can drastically alter how cells respond to treatment. CRISPR therapies are relatively untested in these complex scenarios, which needs to change for them to be considered as broad-scale and viable therapy options.

If the complexity was not problem enough, the final hurdle is scale. A drug is not developed if it cannot be manufactured and mass produced, meaning we need to start thinking this way about CRISPR. How do we really scale up the therapies so that they can be widely used to treat disease?

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Cosimo Ducani PhD is the CEO and Co-Founder of Moligo Technologies. He was previously a post-doctoral fellow at the Karolinska Institute, Sweden, where he researched DNA nanotechnology. Dr Ducani was a Marie Curie Early Stage Researcher at the University of Birmingham, UK, studying the interactions of synthetic drugs and proteins. His work has often centered on the intersection of synthetic biology and DNA nanotechnology. Dr Ducani received fellowships from the Hagelén Foundation and the Swedish Society for Medical Research. He has a Doctorate in Applied Chemistry from the University of Bari, Italy, and Bachelor’s and Master’s degrees in Biotechnology from the University of Salento, Italy
spacer
Cosimo Duncani
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Avacta Announces FDA Approval of its Investigational New Drug (IND) Application for AVA6000

Cambridge and Wetherby, UK, 29 November 2021: Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce that the US Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for AVA6000. This will allow the Group to expand its Phase 1 clinical trial, ALS-6000-101, into clinical trial sites in the United States.
More info >>

White Papers

PhlexEarchive: The Right Solution for Electronic Archiving of TMF Content

Phlexglobal Ltd

Many sponsor organizations have already recognized the value of moving from paper to electronic Trial Master Files (eTMFs). But few sponsors have taken a more holistic approach to the TMF lifecycle and looked at the entire process from study start-up through archiving of the TMF in electronic format, also known as e-archiving. The recurring value of managing, tracking, maintaining and accessing electronic files should not stop at the point of archiving. All of the challenges of managing an active paper TMF carry through to a paper archive. All of the benefits of an electronic TMF also carry through to the electronic archive. As companies look to move their compliance assets to secure, long-term storage, it is important to consider ongoing compliance requirements, security, accessibility, efficiency and costs of archiving TMF content in a digital format.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement